Rostock International Parkinson’s Disease Study - An international, multicentre, epidemiological observational study
Parkinson’s disease (PD) is mostly considered an idiopathic disease, however more and more data suggest that it is a disease that involves interaction of genetic and environmental factors. The most common monogenic form and the one most closely resembling idiopathic PD is LRRK2 (Leucine-rich repeat kinase 2 gene) associated PD.
This research study aims to identify LRRK2-positive patients, non-LRRK2 PD patients (including a subset of patients with monogenic PD other than LRRK2) and to establish a biomarker in the LRRK2-positive cohort.
Who may be eligible to participate?
Men and women 18 years of age and older who are clinically diagnosed with Parkinson‘s disease or is a family member of a patient with LRRK2 parkinsonism or is a member of a high risk population with an early PD onset.
Other inclusion and exclusion criteria may apply.
What does participation involve?
Qualified subjects will participate in one study visit that will last approximately one hour. One blood sample (approximately 1 mL) will be taken and a neurological examination will take place.
Pinky Agarwal, MD, FAAN, Booth Gardner Parkinson’s Care Center